Growth patterns and their contributing factors among HIV-exposed uninfected infants

Aminata Ndiaye1, Klara Suneson1,2, Irene Njuguna3,4

  • 1Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.

Insights

Most infants born to HIV-positive mothers are uninfected, but their growth patterns are not fully understood. Longer maternal antiretroviral therapy (ART) exposure and lower maternal education negatively impacted infant growth, especially with formula feeding.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Public Health

Background:

  • Expanded HIV treatment has increased the number of uninfected infants born to HIV-positive mothers.
  • Growth patterns and determinants in HIV-exposed uninfected (HEU) infants require further investigation.

Purpose of the Study:

  • To assess growth patterns in HEU infants.
  • To identify maternal and infant factors associated with growth in HEU infants.

Main Methods:

  • Longitudinal cohort study of HEU infants from birth to 48 weeks.
  • Anthropometric measurements used to calculate weight-for-age, weight-for-length, and length-for-age z-scores.
  • Linear mixed regression models analyzed associations between growth and maternal/infant factors.

Main Results:

  • Infant length-for-age z-scores were lower in infants delivered via caesarean section.
  • Infant weight-for-age and length-for-age z-scores were lower with longer maternal antiretroviral therapy (ART) exposure.
  • Lower maternal education was associated with depressed weight-for-age and length-for-age z-scores, particularly when not exclusively breastfed.

Conclusions:

  • Infant growth in HEU populations is influenced by multiple factors.
  • Caesarean delivery, prolonged maternal ART exposure, and lower maternal education are associated with poorer infant growth.
  • Intervention strategies should focus on these identified determinants to support optimal growth in HEU infants.

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.6K
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
595
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
13.1K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
112
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.7K